A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 8, 2021

Primary Completion Date

October 19, 2022

Study Completion Date

January 11, 2023

Conditions
Chronic Heart Failure With Reduced Ejection Fraction
Interventions
DRUG

IONIS-AGT-LRx

Multiple doses of IONIS-AGT-LRx will be administered by SC injection.

DRUG

Placebo

IONIS-AGT-LRx-matching placebo will be administered by SC injection.

Trial Locations (19)

5900

Kardiologiai Maganrendeles es Klinikai Vizsgalohely, Orosháza

23510

York Clinical Research LLC, Norfolk

33016

New Generation of Medical Research, Hialeah

34429

Nature Coast Clinical Research - Crystal River, Crystal River

45219

The Lindner Center for Research and Education at The Christ Hospital, Cincinnati

48197

Michigan Heart, Ypsilanti

63136

St. Louis Heart and Vascular Cardiology, St Louis

72205

Arkansas Cardiology, Little Rock

73135

South Oklahoma Heart Research, Oklahoma City

73159

Newton Clinical Research, Oklahoma City

75013

North Texas Research Associates, Allen

H-1122

Semmelweis Egyetem - Varosmajori Sziv es Ergyogyaszati Klinika, Budapest

30-082

Specjalistyczna Praktyka Lekarska, Krakow

92-213

Samodzielny Publiczny ZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego, Lodz

94-255

Indywidualna Specjalistyczna Praktyka Lekarska, Lodz

41-710

AKA-MED Centrum Spólka z Ograniczona Odpowiedzialnoscia, Ruda Śląska

81-717

NZOZ Pro Cordis Sopockie Centrum Badan Kardiologicznych, Sopot

50-556

Centrum Chorob Serca w USK, Wroclaw

50-981

4 Wojskowy Szpital Kliniczny z Poliklinika Samodzielny Publiczny ZOZ we Wroclawiu, Wroclaw

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY